Q2 sales rose 14% year-over-year to NOK 43.6 million, led by strong Cystatin C and U.S. growth. Gross margin dropped to 44% due to one-off production issues, but margins are expected to recover. NT-proBNP assay development remains on track for 2026 launch.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.